Literature DB >> 12174737

Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression.

Zindel Segal1, Pierre Vincent, Anthony Levitt.   

Abstract

There is a growing recognition that relapse and recurrence after the successful treatment of major depression is a common and debilitating outcome that has massive social costs. Although many patients achieve a sustained recovery with maintenance pharmacotherapy, the long-term outcome for a significant proportion of patients is still poor. The purpose of this review is to evaluate the role of combined psychological and pharmacological therapies in minimizing relapse and recurrence in the treatment of depression. Three approaches have been investigated: concurrent treatment, sequential treatment and crossover treatment. Concurrent therapy is as effective as monotherapy for the treatment of mild-to-moderate depressive disorder and shows evidence of a potential treatment advantage in cases where depression is more severe. Consecutive sequencing of pharmacotherapy and psychotherapy has demonstrated some benefit for both the conversion of partial to full response and the prevention of relapse and recurrence, especially in more severely depressed patients. Crossover treatments during the maintenance phase (i.e., switching patients from one treatment to a second after an adequate response to the first) show evidence of being beneficial in preventing relapse and recurrence. Variants of cognitive therapy that have been modified to specifically address residual symptoms in patients who have recovered from depression appear to be the most effective. A review of the studies to date indicates that cognitive therapy may play a role in improving remission rates and decreasing relapse and recurrence rates. Although most studies are small, there is a consistent suggestion of superior prophylaxis for patients receiving some type of sequenced or crossover treatment in which the delivery of antidepressant medication and structured antidepressant psychotherapy is combined. These approaches warrant greater attention; they may present another route for enhancing long-term recovery from major depression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174737      PMCID: PMC161662     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  21 in total

1.  Three-year outcomes for maintenance therapies in recurrent depression.

Authors:  E Frank; D J Kupfer; J M Perel; C Cornes; D B Jarrett; A G Mallinger; M E Thase; A B McEachran; V J Grochocinski
Journal:  Arch Gen Psychiatry       Date:  1990-12

2.  Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years.

Authors:  C F Reynolds; E Frank; J M Perel; S D Imber; C Cornes; M D Miller; S Mazumdar; P R Houck; M A Dew; J A Stack; B G Pollock; D J Kupfer
Journal:  JAMA       Date:  1999-01-06       Impact factor: 56.272

3.  Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.

Authors:  J D Teasdale; Z V Segal; J M Williams; V A Ridgeway; J M Soulsby; M A Lau
Journal:  J Consult Clin Psychol       Date:  2000-08

4.  Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression.

Authors:  E Frank; V J Grochocinski; C A Spanier; D J Buysse; C R Cherry; P R Houck; D M Stapf; D J Kupfer
Journal:  J Clin Psychiatry       Date:  2000-01       Impact factor: 4.384

5.  Prevention of relapse in residual depression by cognitive therapy: a controlled trial.

Authors:  E S Paykel; J Scott; J D Teasdale; A L Johnson; A Garland; R Moore; A Jenaway; P L Cornwall; H Hayhurst; R Abbott; M Pope
Journal:  Arch Gen Psychiatry       Date:  1999-09

6.  Interpersonal psychotherapy (IPT) and drugs in the treatment of depression.

Authors:  G L Klerman; M M Weissmann
Journal:  Pharmacopsychiatry       Date:  1987-01       Impact factor: 5.788

7.  Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression.

Authors:  G E Murphy; A D Simons; R D Wetzel; P J Lustman
Journal:  Arch Gen Psychiatry       Date:  1984-01

8.  Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year.

Authors:  A D Simons; G E Murphy; J L Levine; R D Wetzel
Journal:  Arch Gen Psychiatry       Date:  1986-01

9.  A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both.

Authors:  I M Blackburn; K M Eunson; S Bishop
Journal:  J Affect Disord       Date:  1986 Jan-Feb       Impact factor: 4.839

10.  The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination.

Authors:  I M Blackburn; S Bishop; A I Glen; L J Whalley; J E Christie
Journal:  Br J Psychiatry       Date:  1981-09       Impact factor: 9.319

View more
  11 in total

Review 1.  Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.

Authors:  Benji T Kurian; Tracy L Greer; Madhukar H Trivedi
Journal:  Expert Rev Neurother       Date:  2009-07       Impact factor: 4.618

2.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

3.  Use of psychotherapy for depression in older adults.

Authors:  Wenhui Wei; Usha Sambamoorthi; Mark Olfson; James T Walkup; Stephen Crystal
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

Review 4.  [Inpatient treatment of depression. Should one combine psychotherapy and drugs?].

Authors:  T J Huber
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

5.  Efficacy of mindfulness-based addiction treatment (MBAT) for smoking cessation and lapse recovery: A randomized clinical trial.

Authors:  Jennifer Irvin Vidrine; Claire Adams Spears; Whitney L Heppner; Lorraine R Reitzel; Marianne T Marcus; Paul M Cinciripini; Andrew J Waters; Yisheng Li; Nga Thi To Nguyen; Yumei Cao; Hilary A Tindle; Micki Fine; Linda V Safranek; David W Wetter
Journal:  J Consult Clin Psychol       Date:  2016-09

6.  The effects of centralised and specialised combined pharmacological and psychological intervention compared with decentralised and non-specialised treatment in the early course of severe unipolar and bipolar affective disorders--design of two randomised clinical trials.

Authors:  Lars Vedel Kessing; Hanne Vibe Hansen; Ellen Margrethe Christensen; Henrik Dam; Christian Gluud; Jørn Wetterslev
Journal:  Trials       Date:  2011-02-03       Impact factor: 2.279

Review 7.  Antidepressants and psychotherapy: a clinical research review.

Authors:  Ellen Frank; Danielle Novick; David J Kupfer
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

8.  Psychotherapy as a treatment modality for psychiatric disorders: Perceptions of general public of Karachi, Pakistan.

Authors:  Abdul Mueed Zafar; Ali Jawaid; Hiba Ashraf; Ambreena Fatima; Rubina Anjum; Salah U Qureshi
Journal:  BMC Psychiatry       Date:  2009-06-15       Impact factor: 3.630

Review 9.  A systematic review of comparative efficacy of treatments and controls for depression.

Authors:  Arif Khan; James Faucett; Pesach Lichtenberg; Irving Kirsch; Walter A Brown
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  'Third wave' cognitive therapy versus mentalization-based therapy for major depressive disorder. A protocol for a randomised clinical trial.

Authors:  Janus Christian Jakobsen; Christian Gluud; Mickey Kongerslev; Kirsten Aaskov Larsen; Per Sørensen; Per Winkel; Theis Lange; Ulf Søgaard; Erik Simonsen
Journal:  BMC Psychiatry       Date:  2012-12-19       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.